Floatz logo

Valganciclovir

Epstein-Barr Virus-Associated Lymphoproliferative Disorder

Viracta Therapeutics, Inc.Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Epstein-Barr Virus-Associated Lymphoproliferative Disorder cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB
Retrovir
University of Miami
Phase 2CCC
Methotrexate
University of Miami
Phase 2CCC
Arginine Butyrate
HemaQuest Pharmaceuticals Inc.
Phase 2CCC
Rituximab
University of Miami
Phase 2CCC

View all 17 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionActive
BB
Indicative · Phase 3
68 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative · Phase 2
61 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
B
Indicative · Phase 4
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →